Cardiol Therapeutics (NASDAQ:CRDL) versus PharmaCyte Biotech (OTCMKTS:PMCBD) Critical Comparison

PharmaCyte Biotech (OTCMKTS:PMCBD) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Profitability

This table compares PharmaCyte Biotech and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Cardiol Therapeutics	N/A	-194.40%	-129.07%

Analyst Recommendations

This is a summary of recent ratings for PharmaCyte Biotech and Cardiol Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	0.00
Cardiol Therapeutics	0	0	5	2	3.29

Cardiol Therapeutics has a consensus target price of $8.40, suggesting a potential upside of 546.15%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than PharmaCyte Biotech.

Earnings and Valuation

This table compares PharmaCyte Biotech and Cardiol Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$20.84 million	($0.39)	-3.33

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

PharmaCyte Biotech has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Summary

Cardiol Therapeutics beats PharmaCyte Biotech on 7 of the 10 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.